The neural cell-specific N1 exon of the c-src pre-mRNA is both negatively regulated in nonneural cells and positively regulated in neurons. We previously identified conserved intronic elements flanking N1 that direct the repression of N1 splicing in a nonneural HeLa cell extract. The upstream repressor elements are located within the polypyrimidine tract of the N1 exon 3 splice site. A short RNA containing this 3 splice site sequence can sequester trans-acting factors in the HeLa extract to allow splicing of N1. We now show that these upstream repressor elements specifically interact with the polypyrimidine tract binding protein (PTB). Mutations in the polypyrimidine tract reduce both PTB binding and the ability of the competitor RNA to derepress splicing. Moreover, purified PTB protein restores the repression of N1 splicing in an extract derepressed by a competitor RNA. In this system, the PTB protein is acting across the N1 exon to regulate the splicing of N1 to the downstream exon 4. This mechanism is in contrast to other cases of splicing regulation by PTB, in which the protein represses the splice site to which it binds.
Alternative splicing provides a versatile pathway for generating multiple mRNAs and hence protein products from a single gene (reviewed in references 1 and 14) . Regulatory proteins and their target cis-acting RNA elements modulate the interactions of the general splicing apparatus with certain splice sites in a pre-mRNA and often act in response to developmental or environmental cues. Different splicing patterns can be under either positive or negative control. Negative regulatory elements function to reduce the use of specific splice sites (2, 4, 13, 15, 16, 19, 22-24, 26, 28, 30, 39, 41, 47, 51) . Some repressor elements are thought to obstruct their target splice sites by forming stable secondary structures (19, 31, 49) . Other elements apparently bind to trans-acting protein factors that actively block the use of particular splice sites (2, 15, 24, 28, 32, 45, 47) . However, only a few systems of regulated splicing have been characterized in detail, and for the most part of the mechanisms and molecules that control alternative splicing are poorly understood.
In Drosophila melanogaster, regulated splicing events play a central role in somatic sexual differentiation (reviewed in reference 36). The Sex-lethal (Sxl) protein is produced in female flies, where it regulates the splicing of the next factor in the sex determination pathway, transformer (tra). In the absence of Sxl, a strong default 3Ј splice site in the tra exon 3 is selected, producing a truncated and inactive form of the Tra protein (10, 12) . In female flies, Sxl binds directly to this default 3Ј splice site and prevents binding of the required splicing protein, U2 auxiliary factor (U2AF) (27, 54) . This shifts the splice site choice to a weaker female-specific 3Ј splice site downstream and produces the mRNA for the active female-specific Tra protein (10, 50) . Sxl also autoregulates its own transcript in female flies by promoting the skipping of a male-specific exon, containing a premature stop codon (5, 45) . In this case, Sxl proteins bind to uridine-rich sequences flanking the male-specific sxl exon (26, 46) . These Sxl proteins are thought to interact with the U1 and U2 small nuclear ribonucleoprotein particles (snRNPs) bound at the 5Ј and 3Ј splice sites of the exon, preventing their use in the splicing reaction (17) . Thus, splicing repression by Sxl exhibits two distinct mechanisms. In the tra transcript, Sxl competes with U2AF for binding directly to a 3Ј splice site, whereas in the sxl transcript, multiple Sxl proteins bind distally to the regulated splice sites, apparently preventing the assembled U1 and U2 snRNPs from interacting with other general splicing factors.
In mammalian cells, the polypyrimidine tract binding protein (PTB) is implicated in the alternative splicing of several pre-mRNAs (32, 38, 40, 48) . Exon 7 of the rat ␤-tropomyosin pre-mRNA is repressed in nonmuscle cells by sequence elements in the exon and its upstream 3Ј splice site (24) . The 3Ј splice site of exon 7 contains one or more high-affinity binding sites for PTB, and recombinant PTB outcompetes U2AF for binding to this sequence in vitro (48) . In ␣-tropomyosin, exon 3 is flanked by two repressor elements that induce exon 3 skipping in smooth muscle cells (22) . One of these elements is in the polypyrimidine tract, and the other is located about 200 nucleotides (nt) downstream of the exon. These elements were also found to bind to PTB (42, 48) . The splicing of exon 3 in vitro is inhibited by the addition of PTB (32) . Significantly, this inhibition can be counteracted by preincubating the transcript with U2AF (32) . For the rat fibronectin EIIIB exon, the binding of PTB in lieu of U2AF to the 3Ј splice site also correlates with the inhibition of the splice site (40) . Thus, in these systems, PTB is apparently in competition with U2AF for binding to a polypyrimidine tract and this binding represses splicing in a manner analogous to the effect of Sxl on tra splicing.
We are using the mouse c-src gene as a model to study the mechanisms of neuron-specific splicing. In neurons, the short 18-nt N1 exon is included between the constitutive src exons 3 and 4 (29, 34) . The N1 exon is skipped in other tissues. c-src splicing regulation can be studied in vitro with nuclear extracts from HeLa cervical carcinoma and WERI-1 retinoblastoma cells (8) . The N1 exon is spliced into an src RNA in WERI-1 extract but skipped in HeLa extract (8, 15) . These studies indicate that at least three factors contribute to the neuronspecific pattern of N1 exon splicing. First, the suboptimal length of exon N1 reduces its constitutive use in nonneural cells (7) . The short length of exon N1 may prevent positive exon-bridging or exon definition interactions needed for efficient splicing (6, 9, 15, 44) . Second, a splicing repressor activity in the HeLa extract further represses the exon in nonneural cells (15) . Finally, a splicing enhancer activity activates N1 splicing in the WERI-1 extract (8, 37 ). An intronic splicing enhancer sequence is located between 17 and 142 nt downstream of exon N1 and is essential for the inclusion of the exon in neurons. The conserved core of this sequence binds to a set of proteins to form a neuron-specific splicing enhancer complex (37) . This complex activates N1 exon splicing by as yet unknown mechanisms.
In HeLa extracts, the skipping of exon N1 is directed by repressor elements flanking the exon. Four conserved repeats of the sequence CUCUCU were found to be essential for the repression in vitro (15) . Two of these repeats are within the polypyrimidine tract of the N1 3Ј splice site, and two repeats are found at nt 52 to 57 and 94 to 99 downstream of exon N1. We have now examined the protein factors binding to the N1 polypyrimidine tract and assayed their effect on c-src splicing in vitro. We report the transcript-specific binding of PTB to the N1 polypyrimidine tract. We find that, beyond simply blocking U2AF binding, PTB can apparently repress the splicing of a downstream intron by binding to the upstream 3Ј splice site.
MATERIALS AND METHODS
DNA constructions and RNA transcription. All DNA constructs were made by standard cloning techniques (3). The BS7, BS50, and BS73 constructs were described previously (15) . The BS110, BS111, and BS112 plasmids were constructed by deleting the 3Ј half of exon 3 and the 5Ј half of the intron between exons 3 and N1 (Asp718 to ApaI) from longer two-intron src constructs. These short src constructs are similar to BS7 minus the exon 3 sequences. BS110 has the same N1 branchpoint mutation as BS51 (15) . BS111 has the same purine mutation as BS73. These mutations are shown in Fig. 1A . BS112 has the N1 3Ј splice site replaced with the 3Ј splice site from the human ␤-globin exon 2 similar to BS74 (15) . The TS2 and TS3 clones were made by primer-directed PCR mutagenesis in the BS7 backbone. These mutations at the CUCUCU repeats are shown in Fig. 5A . All DNA clones are under the control of the T7 bacteriophage promoter and were transcribed as previously described (15) . All RNAs used as splicing substrates were transcribed from templates linearized at the NotI site within exon 4. RNAs used for binding reactions or as unlabeled competitors were transcribed from templates linearized at the Bsu36I site terminating one base before exon N1.
In vitro splicing reactions. Nuclear extracts were prepared and in vitro splicing reactions were carried out as described previously (15) . These reactions contain 12 mM HEPES (pH 7.5), 48 mM potassium glutamate, 2.2 mM MgCl 2 , 0.4 mM ATP, 20 mM creatine phosphate, 0.12 mM EDTA, 0.12 mM phenylmethylsulfonyl fluoride, 0.6 mM dithiothreitol, 800 U of RNAguard (Pharmacia) per ml, 2% polyethylene glycol (molecular weight, 3,300), and 12% glycerol in a total volume of 25 l. Extract (190 g of total protein) was preincubated with RNA competitor for 10 min at 30°C. Following the addition of 50,000 cpm (Ϸ1.6 fmol) of labeled transcript and varying amounts of purified protein, the resulting mixture was incubated at 30°C for 4 h.
RNA binding reactions. RNA binding reactions were performed under the same conditions as the in vitro splicing reactions with the following changes. Nuclear extract (25 to 45 g of total protein) was preincubated with the RNA competitor for 10 min at 30°C. Following the addition of 100,000 cpm (Ϸ15 fmol) of labeled probe, the reaction mixture was incubated at 30°C for 15 min. Yeast tRNA (0.4 mg/ml; Boehringer Mannheim) or heparin (200 ng/ml; Calbiochem) was added as a nonspecific competitor. RNase inhibitor and polyethylene glycol were omitted from these reactions. The UV cross-linking studies and electrophoretic mobility shift assay used 25 and 45 g of total protein per reaction, respectively. For the antibody supershift and the immunoprecipitation studies, 35 g of total protein was used per reaction.
Electrophoretic mobility shift assay and antibody supershift assay. One-fifth (5 l) of each binding reaction mixture was loaded onto a 4.5% polyacrylamide (29:1) gel (17 cm by 15 cm by 0.8 mm) with 2.5% (vol/vol) glycerol, prerun at 175 V for 30 min in Tris-glycine electrophoresis buffer (50 mM Tris base, 380 mM glycine, 2.1 mM EDTA). Bromophenol blue marker was loaded on a parallel lane. The binding reaction mixtures were resolved for 2 h at 175 V at room temperature until the dye had migrated Ϸ13 cm. For the antibody supershift experiment, 1 l of serum or ascites was added to each binding reaction mixture and incubated for an additional 8 min at 30°C before being loaded onto the native gel. The PTB and PTB-associated splicing factor (PSF) rabbit antisera were gifts of J. Patton (Vanderbilt University). The heterogeneous nuclear ribonucleoprotein particle (hnRNP) A1 (9H10), hnRNP C (4F4), hnRNP K and J (3C2), and hnRNP H and F (8A6) antibodies were gifts of G. Dreyfuss (University of Pennsylvania).
UV photocross-linking and immunoprecipitation. Following the binding reaction described above, the reaction mixtures were UV irradiated (254 nm) at 2.2 mW/cm 2 for 12 min with a handheld UV lamp (UVP). The RNA in each mixture was degraded with 2 g of RNase A (Sigma) for 30 min at 30°C. As shown in Fig.  5B , RNase T 1 (10 U; Boehringer Mannheim) was added to help digest these longer RNAs. The labeled cross-linked proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and visualized on a PhosphorImager (Molecular Dynamics).
For the immunoprecipitation experiments, protein A-Sepharose beads (10 l; Pharmacia) were bound to antibodies for 1 h at 4°C. The beads were then washed twice with TSA buffer (10 mM Tris-Cl [pH 8], 140 mM NaCl, 0.025% NaN 3 ) plus 0.1% Triton X-100 and 0.1% bovine serum albumin, followed by two washes with TSA and then 50 mM Tris-Cl, pH 6.8 (3). Standard UV cross-linking reaction mixtures as described above were added to the antibody-bound beads, allowed to mix for 1 h at 4°C, and washed as described above. The beads were boiled in SDS-PAGE loading buffer for 5 min, and the proteins were resolved as described above. Rabbit polyclonal antiserum was raised against bacterially expressed recombinant PTB by Animal Pharm Services, Inc., or obtained from J. Patton.
PTB purification. The purification was carried out as described elsewhere (43), except for the following changes. The starting nuclear extracts were in buffer DG with 80 mM potassium glutamate instead of buffer D with 100 mM KCl (8) . The heparin and poly(U)-Sepharose eluates were diluted to 150 mM KCl with buffer A for loading onto the next column. For the Cibacron blue chromatography, the 0.75 M KCl-poly(U)-Sepharose eluate was loaded onto a blue Sepharose 6 Fast Flow (Pharmacia) column in buffer A plus 150 mM KCl and washed in an excess of 10 column volumes of the loading buffer, and PTB was step eluted with 10 column volumes of buffer A plus 500 mM KCl.
RESULTS
A specific protein complex assembles on the N1 3 splice site. Previous mutagenesis analyses showed that splicing of the intron downstream of src exon N1 is repressed in vitro by the 3Ј splice site of the upstream intron (Fig. 1A) . Two repeats of the sequence CUCUCU within the polypyrimidine tract of the N1 3Ј splice site are necessary for this repression (15) . When a short RNA containing the N1 3Ј splice site is added to HeLa splicing extract, splicing of an N1 exon substrate is derepressed, indicating that titratable factors bind to this sequence to mediate its effect. To identify proteins that interact with this repressor element, we created short RNA probes containing the src N1 polypyrimidine tract and two mutant polypyrimidine tracts that do not repress src splicing (Fig. 1A) . The BS110-Bsu RNA has the N1 3Ј splice site with the branchpoint AG changed to CC. As shown previously, this RNA is able to bind and compete away the splicing repressor activity in HeLa nuclear extract (Fig. 1B, lanes 3 and 4) (15) . The BS111 RNA has a mutation within the CUCUCU repeats, and the BS112 RNA substitutes a human ␤-globin 3Ј splice site for the N1 3Ј splice site. Both of these mutations eliminate the repression of downstream intron splicing when present in the splicing substrate itself (15) . Similarly, both mutant RNA competitors failed to titrate away the repressor activity found in the HeLa nuclear extract (Fig. 1B, lanes 5 to 8) .
RNA binding activities in the nuclear extract were assayed by electrophoretic mobility shift assays (Fig. 2) . After incubation in the HeLa extract, the RNA probes were resolved on nondenaturing gels. Complexes formed on all three probes as indicated by their shift in mobility upon incubation in extract. The BS110 RNA was bound predominantly in a unique lowmobility complex called the N1 polypyrimidine tract (N1pt) complex ( Fig. 2A; compare lane 2 to lanes 3 and 4) . The BS111 and BS112 probes exhibited different sets of complexes (lanes 3 and 4). In the gel shown in Fig. 2 , a less intense complex similar to the N1pt complex formed on the BS112 RNA. However, the presence of this complex was variable. To determine the sequence specificity of the N1pt complex, we preincubated the nuclear extract with unlabeled RNA competitors in excess of the labeled BS110 probe. The N1pt complex was nearly eliminated at 100 nM BS110 competitor (Fig. 2B, lane 5) . This is a 167-fold molar excess of unlabeled competitor over the labeled probe. The same concentration of BS111 or BS112 competitor RNA had little or no effect on the N1pt complex ( Fig. 2B ; compare lane 5 to lanes 9 and 13). These results confirm the specificity of the complex for the N1 polypyrimidine tract sequence and show a correlation between the formation of this complex and the splicing repressor activity.
PTB is a component of the N1pt complex. To identify proteins binding to the BS110 RNA, we used UV photocrosslinking to covalently attach bound proteins to the labeled RNA. Several proteins cross-linked to the BS110 RNA in HeLa extract, the most prominent of which was a doublet at 60 kDa (Fig. 3A, lane 1) . A similar but less diffuse 60-kDa band was also present in the WERI-1 extract (Fig. 3A, lane 2) . This 60-kDa band was absent in the cross-linking reactions of the BS111 and BS112 RNAs that lack repressor binding (Fig. 3A , lanes 3 and 5). These probes showed distinctly different patterns of protein binding (Fig. 3A, lanes 3 to 6) .
The binding specificity of the 60-kDa doublet was assessed by RNA competition with excess unlabeled RNAs. Like the N1pt complex, the 60-kDa cross-linked band was competed by the BS110 RNA and not by the mutant RNAs ( Fig. 3B ; compare lanes 2 to 4 to lanes 5 to 10). Moreover, the cross-linking of the 60-kDa doublet to the BS110 RNA (Fig. 3B ) was reduced at 40 to 100 nM specific competitor, similar to the binding observed in native gels (Fig. 2B) . The N1pt native gel complex was excised and subjected to UV cross-linking. The cross-linked proteins in the complex, when resolved on an SDS-polyacrylamide gel, included the 60-kDa band (data not shown). The 60-kDa protein is thus a component of the N1pt complex.
To address whether the 60-kDa doublet cross-links to the N1 polypyrimidine tract in the context of a larger spliceable RNA, we created a 349-nt RNA with the radiolabel specifically localized to the 5Ј-terminal 26 nt encompassing the N1 polypyrimidine tract. This RNA was a shortened version of the BS7 splicing substrate extending from the N1 pyrimidine tract to exon 4. UV cross-linking of this longer RNA also showed the 60-kDa doublet as the predominant protein bound to the N1 polypyrimidine tract (data not shown).
Among the abundant hnRNP proteins, the hnRNP A1, C, and I (PTB) proteins are known to bind pyrimidine-rich sequences (11, 20, 21, 35, 52, 53) and were candidates for factors interacting with the N1 polypyrimidine tract. To address whether any of these proteins participate in the formation of the N1pt complex, antibodies were added to the binding reaction mixture. Of the five anti-hnRNP serum samples tested, only antibodies against PTB altered the N1pt complex (Fig.  4A) . Anti-PTB antibodies strongly reduced the mobility of the N1pt complex, indicating the presence of PTB (Fig. 4A, lane  8) . The appearance of two supershift complexes may be due to multiple molecules of PTB in the N1pt complex or to the polyclonal antibodies recognizing multiple epitopes within one molecule of PTB.
PTB migrates as a doublet or triplet around 58 kDa on polyacrylamide gels (20, 21) . Given the similarity in size, we tested whether the cross-linked 60-kDa band is PTB. Indeed, the anti-PTB serum was able to immunoprecipitate the 60-kDa cross-linked band from HeLa and WERI-1 extracts (Fig. 4B,  lanes 4 and 5) , although the immunoprecipitation from the 1, 3, and 5 . The WERI-1 extract cross-linking reactions were loaded in lanes 2, 4, and 6. The BS110, BS111, and BS112 labeled RNA probes were used in lanes 1 and 2, 3 and 4, and 5 and 6, respectively. The 60-kDa cross-linked doublet is indicated by the arrow. The protein size markers are indicated to the left. (B) The HeLa nuclear extract was preincubated with either no RNA competitor (lane 1) or 10 to 100 nM competitor RNA prior to the addition of the labeled BS110 probe. The BS110, BS111, and BS112 RNA competitors were added to lanes 2 to 4, lanes 5 to 7, and lanes 8 to 10, respectively. staining (Fig. 4C) . The upper band of the PTB doublet from WERI-1 extract migrates slightly faster on SDS-PAGE gels than does the upper PTB band from HeLa (filled arrows). The lower PTB band is less abundant in the WERI-1 extract. This explains the appearance of the WERI-1 PTB cross-link as a singlet, whereas the HeLa protein shows a doublet. How the PTB in the two extracts differs, to bring about this change in mobility, is not clear.
In HeLa nuclear extract, PTB was previously reported to be present in a 350-kDa complex along with PSF (42). In our system, an anti-PSF serum did not supershift or disrupt the N1pt complex (Fig. 4A, lane 7) . Moreover, the N1pt complex eluted from S300 and Superose 6 gel filtration columns at approximately 200 kDa (data not shown). Therefore, the PTB found in the N1pt complex appears to be from a population that is not associated with PSF.
PTB binding correlates with repressor binding on RNAs with pyrimidine tract transition mutations. The purine mutation in BS111 effectively destroys the polypyrimidine tract, and the BS112 mutant has the entire 3Ј splice site replaced. The effects of these mutations on PTB binding could be due to a change in the overall pyrimidine content of the splice site rather than to specific changes in the CUCUCU elements. To address this possibility, two additional mutants were generated. These have the CUCUCU elements altered to either all cytosine or all uridine nucleotides, preserving the pyrimidine content of the sequence (Fig. 5A ). These pyrimidine transition mutants were then tested for both PTB and splicing repressor binding.
PTB binding to the wild-type N1 polypyrimidine tract, the purine mutant, and the all-cytosine and all-uridine mutants was measured by UV cross-linking in the HeLa extract. As before, PTB cross-linking to the N1 polypyrimidine tract was nearly eliminated by the purine mutation (Fig. 5B, lane 2) . The crosslinking of PTB to the all-cytosine and all-uridine RNA probes was greatly reduced but not completely eliminated (Fig. 5B,  lanes 3 and 4) . The all-uridine mutant cross-linked strongly to two new proteins of 35 and 40 kDa. These RNAs were also transcribed as unlabeled RNA competitors. When added to UV cross-linking reaction mixtures with the labeled wild-type probe, only the wild-type competitor effectively titrated PTB binding (Fig. 5C ). This confirms that PTB binds well only to the wild-type N1 3Ј splice site and that the CUCUCU repeats are required for this binding.
To measure splicing repressor binding, these unlabeled The HeLa extract was cross-linked to wild-type and mutant RNAs and resolved by SDS-10% PAGE. Proteins cross-linked to labeled probes with wild-type, purine mutant, cytosine mutant, and uridine mutant CUCUCU repeats and the src exon 4 3Ј splice site were loaded in lanes 1 to 5, respectively. Note that these probes are longer than those used for Fig. 3 , producing extra cross-linked bands not seen with the shorter RNA probes. PTB is indicated by the thick arrow. Two new cross-linked bands seen in TS3 are indicated by the thin arrows. The protein size markers are indicated to the left. (C) Cross-linking competition with the pyrimidine mutant RNAs. The HeLa extract was preincubated with no RNA competitor (lane 1) or with 24 nM BS7, BS73, TS2, or TS3 competitor RNA (lanes 2 to 5, respectively). This was followed by incubation with the BS7-Bsu probe and cross-linking. The PTB band is indicated by the arrow. (D) Splicing derepression with the pyrimidine mutant RNAs. Splicing reactions of the BS7 transcript in a HeLa-WERI-1 extract mixture and in HeLa extract were loaded in lanes 1 and 2, respectively. HeLa extracts preincubated with 13 to 100 nM competitor RNA prior to the addition of the BS7 transcript were loaded in lanes 3 to 18. The BS7, BS73, TS2, and TS3 RNA competitors were added to lanes 3 to 6, 7 to 10, 11 to 14, and 15 to 18, respectively. The lariats, unspliced transcript, spliced product, and 5Ј exon intermediate are diagrammed to the left. RNA competitors were titrated into the in vitro splicing reaction mixture. The repressor binding again correlated with the PTB binding. The purine mutant (BS73) RNA failed to titrate away the repressor activity (Fig. 5D, lanes 7 to 10) . Similarly, the cytosine and uridine mutants were much less effective than wild type in derepressing splicing in the HeLa nuclear extract ( Fig. 5D; compare lanes 3 to 6 with lanes 11 to 18) . These results indicate that the ability of RNAs to compete away the repressor activity is a function of their ability to bind PTB.
To address whether PTB could bind to the 3Ј splice site of src exon 4 and inhibit its use in the splicing of exons N1 and 4, we performed UV cross-linking analysis on the exon 4 3Ј splice site (BS50 in Fig. 5A ). PTB cross-linked poorly to the src exon 4 splice site, indicating that this splice site is not the preferred PTB binding site on the src pre-mRNA (Fig. 5B, lane 5) . In previous experiments, the 3Ј splice site of exon 4 did not repress N1 splicing when placed upstream of the N1 exon (15) , extending the correlation between the PTB and repressor binding activities.
Purified PTB can reconstitute splicing repression in a derepressed HeLa nuclear extract. To test whether PTB is indeed the repressor titrated by the N1 polypyrimidine tract RNA competitor, purified PTB was added back to a derepressed HeLa nuclear extract to reestablish splicing repression. As shown in Fig. 6A , the splicing of the c-src pre-mRNA in HeLa nuclear extract was enhanced 10-fold at 100 nM N1 polypyrimidine tract competitor RNA (Fig. 6A; compare lanes  2 and 3) . This enhancement was eliminated by a 48 nM concentration of purified PTB (lane 6). This amount of added PTB is two-to fourfold lower than the endogenous PTB level in HeLa extract as determined by Western blotting (data not shown).
To ensure that the repression did not result from the PTB binding to sequences other than the N1 polypyrimidine tract, purified PTB was added to the reaction mixture of a premRNA containing the purine mutation in the N1 polypyrimidine tract (BS73; Fig. 1A ). Unlike the wild-type pre-mRNA, this mutant pre-mRNA was spliced in both WERI-1 and HeLa extracts, and this splicing was slightly enhanced (less than twofold) by the N1pt competitor RNA (Fig. 6A, lanes 10 to 12) . The addition of purified PTB reduced the splicing of the BS73 mutant by about fourfold. In contrast, the added PTB repressed the splicing of the wild-type substrate by over 50-fold. The small reduction in splicing upon PTB addition is consistent with the slight enhancement of BS73 splicing by the competitor RNA. This may be due to PTB binding to the exon 4 3Ј splice 9) . In lanes 3 to 9, the HeLa extract was preincubated with 100 nM BS7-Bsu RNA to titrate away the repressor activity. Purified PTB protein was added to the derepressed extract at 16, 32, and 48 nM final concentrations in lanes 4 to 6, respectively. In lanes 7 to 9, buffer DG was added in the same volumes as with the purified PTB fraction; both the buffer DG and the PTB fraction were concentrated in the same manner. Lanes 10 to 15 show splicing of the BS73 transcript in a WERI-1-HeLa mixture (lane 10) and in HeLa extract (lanes 11 to 15). The BS7-Bsu competitor RNA (100 nM final concentration) was added to the reaction mixtures in lanes 12 to 15. PTB was also added at 16, 32, and 48 nM final concentrations in lanes 13 to 15, respectively. (B) Recombinant hnRNP A1 protein does not repress N1 splicing. Shown in splicing of the BS7 transcript in a WERI-1-HeLa mixture (lane 1) and in a HeLa extract (lanes 2 to 6). In lanes 3 to 6, the HeLa extract was preincubated with 100 nM BS7-Bsu RNA to titrate away the repressor activity. Recombinant hnRNP A1 protein was added to the derepressed extract at 16, 32, and 48 nM final concentrations in lanes 4 to 6, respectively. site or to CUCUCU elements within the intron. These concentrations of competitor RNA and purified PTB have no effect on the splicing of introns derived from the adenovirus major late transcription unit and the human ␤-globin premRNA (data not shown). The BS7 and BS73 RNAs differ only at the N1 3Ј splice site and contain identical spliced introns. We conclude that PTB binds to the N1 polypyrimidine tract to repress the downstream src intron.
To determine if this repression was specific to PTB, we tested whether another protein that bound to polypyrimidine tracts would inhibit splicing. The protein hnRNP A1 was added to extract that had been treated with the N1pt competitor. In contrast to PTB, hnRNP A1 had no effect on BS7 splicing activity (Fig. 6B) .
DISCUSSION
PTB represses src N1 splicing in the HeLa nuclear extract. We showed previously that the N1 3Ј splice site represses splicing of the src N1 exon in vitro. We now show that this repression is likely mediated by PTB. PTB binds to the N1 exon 3Ј splice site but not to several mutant sites. The wild-type site represses splicing of the intron downstream of N1, whereas the mutant sites do not. Moreover, a small RNA containing the N1 polypyrimidine tract can derepress splicing when added to the HeLa extract in excess-competing away the repressing factor(s). When mutant polypyrimidine tracts were tested in this assay, the ability to bind PTB correlated closely with the ability to derepress splicing. Most significantly, purified PTB can reconstitute the repression of N1 splicing in an extract derepressed with the competitor RNA. It is possible that the added PTB is binding the competitor RNA and dissociating some other repressor that then acts on the splicing substrate. However, only 48 nM purified PTB was required to restore the repression in the presence of 100 nM competitor RNA. Thus, the amount of PTB needed to repress splicing correlates well with the amount of RNA needed originally to derepress splicing. This and the binding data for pyrimidine tract mutants suggest that PTB binds directly to the splicing substrate to repress splicing. It is conceivable that other proteins are working in conjunction with PTB, and formal proof that PTB is solely responsible for the repression will require the development of extracts specifically depleted of PTB. This has not proven possible with the tools currently available.
PTB is binding to the N1 polypyrimidine tract across the exon from the repressed intron. Without the CUCUCU elements in the N1 polypyrimidine tract, PTB did not bind to the N1 3Ј splice site and failed to repress splicing from N1 to exon 4. PTB may also bind within the downstream repressed intron. Although PTB binds poorly to the 3Ј splice site of exon 4, there are two CUCUCU elements downstream within the repressed intron that are necessary for the splicing repression (15) . Studies are in progress to examine PTB binding at these sites.
PTB repression of a downstream 5 splice site. PTB was previously shown to be a repressor of specific splicing events, although not in a neural cell-specific system. The most unusual aspect of our results is the location of the PTB binding sites relative to the repressed intron. In this system, PTB binding to a 3Ј splice site resulted in the repression of splicing of the downstream intron. In other systems, PTB directly inhibits splicing at a 3Ј splice site by blocking U2AF binding (32, 48, 54) . The splicing of src exon 3 to N1 may be similarly repressed by PTB binding to the N1 3Ј splice site. However, the splicing event studied here is the splicing of N1 to exon 4. This PTBmediated repression is likely to be targeted in some way to the nearby 5Ј splice site of N1.
PTB may also affect 5Ј splice site use in other systems. The rat ␤-tropomyosin exons 6 and 7 exhibit mutually exclusive splicing (25) . The skeletal muscle-specific exon 7 is negatively regulated in nonmuscle cells by regulatory elements, in the 3Ј splice site, that bind PTB (24, 38, 48) . Interestingly, the inclusion of this exon follows an ordered pathway in which exon 7 is first spliced to exon 8, indicating that the 5Ј splice site of exon 7 is the primary site of regulation (25) . Thus, PTB binding to the 3Ј splice site of exon 7 may negatively affect the use of the 5Ј splice site.
How might PTB repress a downstream 5Ј splice site? By blocking U2AF binding at the 3Ј splice site, PTB could inhibit positive exon-bridging interactions with the downstream 5Ј splice site. However, the splicing from N1 to exon 4 does not require a functional 3Ј splice site upstream and is presumably independent of U2AF binding (15) . The 18-nt src N1 exon is also apparently too short to facilitate exon-bridging interactions (6, 15, 18) . Alternatively, PTB binding may block U1 binding to the 5Ј splice site. Recent evidence that a PTBcontaining polyadenylation enhancer complex can recruit the U1 snRNP to an adjacent RNA binding site suggests a more complicated mechanism than simply obstructing the 5Ј splice site (33) . Instead, the PTB complex may interact with the U1 snRNP at the N1 5Ј splice site and prevent subsequent spliceosome assembly. This is similar to the proposed model for sxl autoregulation in which Sxl proteins are thought to allow initial snRNP binding but block further spliceosome assembly (17) . Studies of the interactions among the N1 polypyrimidine tract, the 5Ј splice site, and the constitutive splicing machinery should help clarify these issues.
Other trans-acting regulators binding to the N1 3 splice site? The complete composition of the N1pt complex is unresolved. Two or three molecules of PTB in the N1pt complex would account for its estimated size of 200 kDa. The ␣-and ␤-tropomyosin regulatory elements were shown to contain more than one PTB binding site (48) . But could PTB be solely responsible for the splicing repression? PTB alone can restore repression to an extract treated with the N1pt competitor. However, additional factors may be present in excess of PTB and are not completely sequestered by the competitor. Several other less intense proteins cross-link to the N1 polypyrimidine tract RNA. These proteins also cross-linked to the mutant 3Ј splice sites, indicating that their binding sites are outside the CUCUCU elements. Although UV cross-linking analysis on the gel-purified N1pt native gel complex revealed only the presence of PTB, other factors may dissociate from the RNA during the electrophoresis or may not cross-link well within the gel. Thus, unidentified proteins may be required within the N1pt complex.
The function of the PTB-N1pt complex under conditions in which splicing is activated is also intriguing. Part of the tissue specificity of N1 splicing resides in factors binding to the enhancer sequence downstream of the exon (37) . Conserved CUCUCU repeats within this region are also required to maintain the splicing repression (15) . It is possible that proteins involved in activation may also interact with the N1 polypyrimidine tract. The substitution of the src N1 3Ј splice site with the exon 4 3Ј splice site abolished N1 splicing in the LA-N-5 neuroblastoma cell line (7) . We find here that PTB binds poorly to the 3Ј splice site of exon 4. These data suggest a role for the N1 3Ј splice site and hence PTB in the neural activation of N1 splicing. PTB may function within a larger complex of proteins bound across the N1 exon region. The addition of cell-type-specific factors to such a complex could alter its properties and interactions with the general splicing machinery.
Judging from their electrophoretic mobilities, the PTB pro-teins from HeLa and WERI-1 extracts are different. It is not clear whether this reflects different isoforms or modifications of the protein. The modification in PTB may alter the splicing repression activity by affecting its interaction with other splicing factors. We are currently examining the differences between the HeLa and the WERI-1 PTB. We have found that adding HeLa PTB at the levels used here to the WERI-1 extract does not repress splicing (data not shown). Systems of regulated splicing are often described in terms of a binary choice between a default splicing pattern and a regulated pattern. The default pattern is defined as that which the general splicing machinery will carry out without extra factors. This default choice is thought to have some competitive advantage over the regulated splicing pattern, such as stronger splice site sequences. Regulatory proteins then act to shift the competition either by enhancing the regulated splice sites or by repressing the default sites. In the case of the N1 exon, neuronal factors are known to be required for the splicing of the exon; hence the default pattern of splicing was proposed to be the exclusion of the exon in nonneuronal cells. It now appears that the exclusion of the N1 exon is maintained by PTB, a regulatory factor not essential for general splicing. Instead of a simple default-versus-regulated choice, both patterns of src splicing appear to be maintained by specific regulatory proteins. It seems likely that similar effects will be observed in other systems in which PTB has been implicated. Rather than being a simple repressor that blocks access to splice sites, PTB may have a broader role of maintaining specific splicing patterns in a variety of cells and conditions, until more specific regulatory signals intervene.
